A new global Tufts CSDD survey of 387 investigative site professionals reveals broad experience with digital and decentralized trial tools, growing site-driven technology investments, and strong ...

A new global Tufts CSDD survey of 387 investigative site professionals reveals broad experience with digital and decentralized trial tools, growing site-driven technology investments, and strong ...

“FDA's talented reviewers have been creative and proactive in deploying AI capabilities—agentic AI will give them a powerful tool to streamline their work and help them ensure the safety and efficacy ...

In today’s ACT Brief, we examine how the FDA’s CNPV Program is reshaping operational planning and accelerated submission ...